HR Execs on the Move

Senseonics

www.senseonics.com

 
Senseonics, Inc. is a medical device startup company in Germantown, Maryland, USA (near Washington, DC) developing transformative glucose monitoring products that are intended to enable people with diabetes to confidently live their lives with ease. Utilizing breakthrough fluorescence sensing technology, the Senseonics continuous glucose monitoring ("CGM") system is being designed to be the first fully implantable CGM that is highly accurate and stable throughout its long sensor life.
  • Number of Employees: 100-250
  • Annual Revenue: $0-1 Million
  • www.senseonics.com
  • 20451 Seneca Meadows Pkwy
    Germantown, MD USA 20876
  • Phone: 301.515.7260

Executives

Name Title Contact Details
Abhi Chavan
VP - Engineering, R&D Profile
Andrew DeHennis
Sr. Director of Engineering, Research and Development Profile

Similar Companies

Softcare

Softcare is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Segra

Our solution: Segra leverages expertise in biochemistry, botany, plant tissue culture, genetic testing, and production under strict regulatory environments to bring end-to-end solutions for product production and sale in the medical Cannabis space.

Thallion Pharmaceuticals

Thallion Pharmaceuticals is a Saint-Laurent, QC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Phosplatin Therapeutics

Phosplatin Therapeutics is a private, clinical stage biopharmaceutical company founded in 2010, and funded by private investors and family investment offices in the U.S., Europe and Asia.

Ansun Biopharm

Ansun BioPharma is a clinical stage biopharmaceutical company focused on the development of unique host-directed anti-viral therapies for respiratory viruses. Ansun BioPharma has two products in late stage clinical development. Fludase is a first-in-class broad-spectrum investigational therapeutic agent to treat all forms of influenza, including pandemic variants and drug-resistant variants that cannot be treated by any currently approved flu therapies, including H1N1, H5N1 and H7N9. Paradase is an investigational nebulized drug which is designed to target the receptor for parainfluenza viruses and is being evaluated in a Phase 2 trial for the treatment of lower tract parainfluenza infection in immunocompromised patients.